This review examines how gut microbiota-derived metabolites regulate immunometabolism in IBD, focusing on their roles in reshaping mitochondrial function, cellular metabolic pathways, and immune cell behavior in the context of dysbiosis.
Microbial metabolites act as key intermediates in host-microbe communication; dysbiosis can perturb immune homeostasis by rewiring host metabolic circuits, and targeting the microbiota-metabolite-immunometabolism axis is proposed as a promising therapeutic strategy in IBD.
As a review, no original clinical or experimental data are presented; the therapeutic concepts discussed are largely preclinical and described as 'underexplored,' limiting direct clinical applicability.
Clinicians managing IBD should watch this space: the microbiota-metabolite-immunometabolism axis is emerging as a novel therapeutic target, though interventions remain investigational and are not yet ready for routine clinical use.
